• Title/Summary/Keyword: Multiple-dose

Search Result 487, Processing Time 0.023 seconds

Use of SGLT2 inhibitor/metformin fixed dose combination in Korea (SGLT2 저해제/metformin 고정용량복합제의 국내 사용 현황)

  • Choi, Ha Eun;Lee, Ji Won;Je, Nam Kyung;Jeong, Kyeong Hye
    • Korean Journal of Clinical Pharmacy
    • /
    • v.32 no.1
    • /
    • pp.13-19
    • /
    • 2022
  • Background: The use of combination therapy and fixed-dose combination therapy is increasing for the treatment of type 2 diabetes. Sodium glucose cotransporter-2 inhibitor (SGLT2i) is a drug class used in combination with metformin. Methods: Type 2 diabetes patients on SGLT2i/metformin combination therapy were extracted from the 2019 Health Insurance Review & Assessment Service-National Patients Sample. On July 1, 2019, SGLT2i and metformin fixed-dose combination (SGLT2i/metformin FDC) and two-pill combination (TPC) groups were identified, and a chi-square test and multiple logistic regression were performed. Results: Of total 2,992 patients, 1,077 (36%) were prescribed SGLT2i/metformin FDC and 1,915 (64%) were prescribed TPC. We found that the most common comorbidities were in the order of dyslipidemia, gastrointestinal disease, and hypertension. Multiple logistic regression analysis showed that the use of SGLT2i/metformin FDC was lower than TPC in patients with diabetic neuropathy (OR=0.76, p=0.008). Clinic (OR=2.09, p<0.001) and general hospital (OR=1.40, p=0.019) showed higher tendency to prescribe SGLT2i/metformin FDC compared to tertiary hospital. The tendency of prescribing SGLT2i/metformin FDC was lower in Kyeonggi (OR=0.79, p=0.037), Gyeongsang (OR=0.77, p=0.025) and Chungcheong (OR=0.68, p=0.007) than Seoul. Conclusion: Factors related to the use of SGLT2i/metformin FDC in patients with type 2 diabetes were complication, medical institution and region. The tendency to prescribe SGLT2i/metformin FDC was relatively higher in clinics than in tertiary general hospitals and in Seoul than in other regions.

Evaluation of the Modified Hybrid-VMAT for multiple bone metastatic cancer (다중표적 뼈 전이암의 하이브리드 세기변조(modified hybrid-VMAT) 방사선치료계획 유용성 평가)

  • Jung, Il Hun;Cho, Yoon Jin;Chang, Won Suk;Kim, Sei Joon;Ha, Jin Sook;Jeon, Mi Jin;Jung, In Ho;Kim, Jong Dea;Shin, Dong Bong;Lee, Ik Jae
    • The Journal of Korean Society for Radiation Therapy
    • /
    • v.30 no.1_2
    • /
    • pp.161-167
    • /
    • 2018
  • Purpose : This study evaluates the usefulness of the Modified Hybrid-VMAT scheme with consideration of background radiation when establishing a treatment plan for multiple bone metastatic cancer including multiple tumors on the same axis. Materials and Methods : The subjects of this study consisted of five patients with multiple bone metastatic cancer on the same axis. The planning target volume(PTV) prescription dose was 30 Gy, and the treatment plan was established using Ray Station(Ray station, 5.0.2.35, Sweden). In the treatment plan for each patient, two or more tumors were set as one isocenter. A volumetric modulated arc therapy(VMAT) plan, a hybrid VMAT(h) plan with no consideration of background radiation, and a modified hybrid VMAT(mh) with consideration of background radiation were established. Then, using each dose volume histogram(DVH), the PTV maximum dose($D_{max}$), mean dose($D_{mean}$), conformity index(CI), and homogeneity index(HI) were compared among the plans. In addition, the organ at risk(OAR) of each treatment site was evaluated, and the total MU(Monitor Unit) and treatment time were also analyzed. Results : The PTV $D_{max}$ values of VMAT, VMAT(h) and VMAT(mh) were 3188.33 cGy, 3526 cGy, and 3285.67 cGy, the $D_{mean}$ values were 3081 cGy, 3252 cGy, and 3094 cGy; the CI values were $1.35{\pm}0.19$, $1.43{\pm}0.12$, and $1.30{\pm}0.06$; the HI values were $1.06{\pm}0.01$, $1.14{\pm}0.06$, and $1.09{\pm}0.02$; and the VMAT(h) OAR value was increased 3 %, and VMAT(mh) OAR value was decreased 18 %, respectively. Furthermore, the mean MU values were 904.90, 911.73, and 1202.13, and the mean beam on times were $128.67{\pm}10.97$, $167.33{\pm}7.57$, and $190.33{\pm}4.51$ respectively. Conclusions : Applying Modified Hybrid-VMAT when treating multiple targets can prevent overdose by correcting the overlapping of doses. Furthermore, it is possible to establish a treatment plan that can protect surrounding normal organs more effectively while satisfying the inclusion of PTV dose. Long-term follow-up of many patients is necessary to confirm the clinical efficacy of Modified Hybrid-VMAT.

  • PDF

Exposure Dose of Thyroid, Breast, and Sexual Gland using a Personal Dosimeter in Multiple CT Examinations (다중 CT 검사 시 개인선량계를 이용한 갑상선, 유방, 생식선의 피폭선량)

  • Kim, Hae-Suk;Kim, Jang-Oh;Lee, Yoon-Ji;Heo, Sung-Hoe;Lee, Chang-Ho;Min, Byung-In
    • Journal of the Korean Society of Radiology
    • /
    • v.14 no.4
    • /
    • pp.345-351
    • /
    • 2020
  • In this study, a dose assessment was conducted on the exposure dose of thyroid, breast and sexual gland using a personal dosimeter in multiple CT examinations currently being conducted in health examinations. The dose assessment was measured by attaching TLD and EPD to the locations of the thyroid, breast and sexual gland during CT examinations of Brain, Brain + C-S, Brain + Low lung, Brain + L-S among CT items. The generated dose of equipment, CTDIvol and DLP, was measured. The study found that effective doses were rated 41.7% higher for thyroid TLD in Brain + C-S CT examinations than for the general public, 156% higher for EPD, 10% for breast EPD in Brain + Low Lung CT examinations, 124.4% higher for reproductive TLD and 339.8% higher for Brain + L-S CT examinations. The CTDIvol and DLP analysis results showed that C-S CTDIvol values were higher than the diagnostic reference levels at 0.6%, Low Lung CTDIvol values at 5.7%, DLP values at 11.8% and L-S CTDIvol values at 1.2%. In order to reduce the exposure dose of patients, indiscriminate examination is reduced and dose limit setting is needed in health examination.

Current Status of High Dose Rate Brachytherapy in Cervical Cancer in Korea and Optimal Treatment Schedule (자궁 경부암 고선량율 강내조사 치료의 국내 현황과 적정 치료방법)

  • Huh, Seung-Jae
    • Radiation Oncology Journal
    • /
    • v.16 no.4
    • /
    • pp.357-366
    • /
    • 1998
  • Brachytherapy is an essential part of radiotherapy for uterine cervical cancer. The low dose rate (LDR) regimen has been the major technique of intracavitary therapy for cervical cancer. However, there has been an expansion in the last 20 years of high dose rate (HDR) machines using Ir-192 sources. Since 1979, HDR brachytherapy has been used for the treatment of uterine cervical cancer in Korea. The number of institutions employing HDR has been increasing, while the number of low dose rate system has been constant. In 1995, there was a total 27 HDR brachytherapy units installed and 1258 cases of patients with cervical cancer were treated with HDR Most common regimens of HDR brachytherapy are total dose of 30-39 Gy at point A with 10-13 fractions in three fractions per week. 24-32 Gy with 6-8 fractions in two fractions per week, and 30-35 Gy with 6-7 fractions in two fractions per week. The average fractionation regimen of HDR brachytherapy is about 8 fractions of 4.1 Gy each to Point A. In Korea, treatment results for HDR brachytherapy are comparable with the LDR series and appears to be a safe and effective alternative to LDR therapy for the treatment of cervical carcinoma. Studies from the major centers report the five-year survival rate of cervical cancer as. 78-86$\%$ for Stage 1, 68-85$\%$ for stage 11, and 38-56$\%$ for Stage III. World-wide questionnaire study and Japanese questionnaire survey of multiple institutions showed no survival difference in any stages and dose-rate effect ratio (HDR/LDR) was calculated to be 0.54 to 0.58. However the optimum treatment doses and fractionation schemes appropriate to generate clinical results comparable to conventional LDR schemes have yet to be standardized. In conclusion, HDR intracavitary radiotherapy is increasingly practiced in Korea and an effective treatment modality for cervical cancer. To determine the optimum radiotherapy dose and fractionation schedule, a nation-wide prospective study is necessary in Korea. In addition, standardization of HDR application (clinical, computer algorithms, and dosimetric aspects) is necessary.

  • PDF

A Study on the Radiation Dose of $^{131}I$ in the Thyroid Gland during the Treatment of Hyperthyroidism (갑상선 기능항진증의 $^{131}I$ 치료시 갑상선 조사량에 관한 연구)

  • Suh, Hwan-Jo;Koh, Chang-Soon;Lee, Mun-Ho
    • The Korean Journal of Nuclear Medicine
    • /
    • v.9 no.1
    • /
    • pp.59-71
    • /
    • 1975
  • 53 patients with hyperthyroidism have been analyzed with special reference to therapeutic response to radioactive iodine ($^{131}I$) treatment. Mean effective half-life, 24 hour uptake rate and radiation dose of $^{131}I$ in hyperthyroid patients included in this study were respectively. 1. Mean effective half-life of $^{131}I\;was\;4.7{\pm}1.5$ days in the tracer dose and $5.0{\pm}1.5$ days in the therapeutic dose. 2. Mean 24 hour uptake rate of $^{131}I\;was\;72.7{\pm}11.1%$ in the tracer dose and $73.4{\pm}12.3%$ in the theapeutic dose. 3. Mean radiation dose of $^{131}I\;was\;5,319{\pm}2,648$ RAD as predicted and $5,692{\pm}2,843$ RAD as actual. A single dose of radioactive iodine treatment was satisfactory in 34 patients (radioiodine sensitive) and multiple doses of radioactive iodine treatments were required in 19 patients (radioiodine resistant). A radioiodine resistant group of patients with hyperthyroidism was distinctively characteristic in the following aspects. 1. Mean thyroid weight calculated in the resistant group ($63.9{\pm}14.0gm$) was significantly (p<0.01) greater than that of the sensitive group ($46.6{\pm}13.3gm$). 2. Mean 24 hour uptake rate of the tracer dose in the resistant group ($67.3{\pm}10.7%$) was significantly (p<0.01) lower than that of the sensitive group ($75.7{\pm}10.5%$). 3. Mean 24 hour uptake rate of the therapeutic dose in the resistant group ($68.5{\pm}13.7%$) was significantly (p<0.05) lower than that of the sensitive group ($76.1{\pm}10.9%$). 4. Mean predicted radiation dose, of $^{131}I$ in the resistant group ($3,684{\pm}1,745$ RAD) was significantly (p<0.01) lower than that of the sensitive group ($6,232{\pm}2,683$ RAD). 5. Mean actual radiation dose of $^{131}I$ in the resistant group ($4,100{\pm}1,691$ RAD) was significantly (p<0.01) lower than that of the sensitive group ($6,582{\pm}3,024$ RAD). 6. No significant difference was detected in terms of effective half-life of $^{131}I$ among the groups (p>0.05). 7. The average mean % difference of effective half-life, uptake rate and radiation dose measured following the tracer and therapeutic dose of $^{131}I$ were not statistically significant (p>0.05). Therefore effective half-life, uptake rate and radiation dose of the therapeutic dose of $^{131}I$ were readily predictable following the tracer dose of $^{131}I$. 8. It is concluded that the possibility of resistance to radioactive iodine treatment may be anticipated in patients with thyroid gland large in size and compromised $^{131}I$ uptake rate.

  • PDF

Saccharomyces cerevisiae의 물질대사에 미치는 중성자의 영향

  • 이민재
    • Journal of Plant Biology
    • /
    • v.7 no.4
    • /
    • pp.9-14
    • /
    • 1964
  • According to the results measured the respiratory quotient of Saccharomyces cerevisiae with neutron radiation by manometric direct method, the respiratory quotient of them was stimulated at the dose(7$\times$106N/$\textrm{cm}^2$/sec) of neutron radiation for 60 seconds, and was inhibited in each group irradiated at the high dose (7$\times$108N/$\textrm{cm}^2$/sec) of neutron. Its physiological effects influenced on neutron had relations with respiratory quotient, reproductive rate and fermentation in the curve of normal logarithmic phase. The multiple reactions which appeared in yeast, indicated that a great deal of physiological function were closely correlated with the irradiated dosage of neutron. The kinds of free amino acid in yeast irradiated with neutron were different from those of unirradiated yeast. The activityof dehydrogenase system accelerated the metabolic function of yeast irradiated at some low dose of neutron. By this results, it may demonstrate that the fact which the phenomena obtained in the stimulation of neutron possess its character for several generation, is dependent on the theory of mutation. Subsequently, it seemed reasonable certain dominant type of microorganisms.

  • PDF

Usefulness assessment of the Volumetric Modulated Arc Therapy technique for reducing low-dose areas during radiotherapy for patients with multiple metastatic cancers (다발성 전이암 환자의 방사선치료 시 저선량 영역 감소를 위한 용적조절 회전 방사선치료(Volumetric Modulated Arc Therapy) 기법의 유용성 평가)

  • Yun-won Choi;Dong-min Jeong;Se-young Kim;Ryeong-hwang Park;I-ji Kim;Yong-wan Cho;Yongjae Kwon;Byeol-nim Park;Gyeong-min Yoo;Ho-kyung Moon;Dong-jae Jang;Jae-young Lee;Dayoung Lim;Sang-gyu Lee;Jong-geol Baek
    • The Journal of Korean Society for Radiation Therapy
    • /
    • v.35
    • /
    • pp.23-31
    • /
    • 2023
  • Purpose: The purpose of this study is to evaluate the usefulness of Non-Treat Functionality Volumetric Modulated Arc Therapy(NTF-VMAT) and Treat Functionality VMAT(TF-VMAT) treatment plans in reducing the low-dose area during radiation therapy for patients with multiple metastatic cancers. Materials and Methods: The study was conducted on an Arccheck phantom, treatment planning target locations were set in pairs at intervals of 2 cm, 4 cm, and 6 cm on the X, Y, and Z axes. Based on these location settings, the volume of the low-dose area in NTF-VMAT and TF-VMAT was measured and compared. Results: The results of the study showed that, within a prescription dose range of 10% ~ 70%, the difference in low-dose area volumes across each axis was as follows: On the X-axis, there was a maximum difference of -47.6% and a minimum difference of -2.2%. On the Y-axis, there was a maximum difference of -17.5% and a minimum difference of -7.3%. The Z-axis showed a maximum difference of -39.7%, with the smallest difference being -6.8%. Conclusion: In radiation therapy for patients with multiple metastatic cancers, the TF-VMAT treatment plan was able to reduce the low-dose area by 10-40% compared to NTF-VMAT. This suggests that utilizing Treat Functionality, which includes the Island block technique, improves dose distribution and minimizes side effects, making it beneficial for the treatment of patients with multiple metastatic cancers.

  • PDF

Assessment of the Glycophorin A Mutant Assay as a Biologic Marker for Low Dose Radiation Exposure (저선량 방사선 노출에 대한 생물학적 지표로서 Glycophorin A 변이발현율 측정의 유용성 평가)

  • Ha, Mi-Na;Yoo, Keun-Young;Ha, Sung-Whan;Kim, Dong-Hyun;Cho, Soo-Hun
    • Journal of Preventive Medicine and Public Health
    • /
    • v.33 no.2
    • /
    • pp.165-173
    • /
    • 2000
  • Objectives : To assess the availability of the glycophorin A (GPA) assay to detect the biological effect of ionizing radiation in workers exposed to low-doses of radiation. Methods : Information on confounding factors, such as age and cigarette smoking was obtained on 144 nuclear power plant workers and 32 hospital workers, by a self-administered questionnaire. Information on physical exposure levels was obtained from the registries of radiation exposure monitoring and control at each facility. The GPA mutant assay was performed using the BR6 method with modification by using a FACScan flow cytometer. Results : As confounders, age and cigarette smoking habits showed increasing trends with GPA variants, but these were of no statistical significance. Hospital workers showed a higher frequency of the GPA variant than nuclear power plant workers in terms of the NO variant. Significant dose-response relationships were obtained from in simple and multiple linear regression models. The slope of the regression equation for nuclear power plant workers was much smaller than that of hospital workers. These findings suggest that there may be apparent dose-rate effects. Conclusion : In population exposed to chronic low-dose radiation, the GPA assay has a potential to be used as an effective biologic marker for assessing the bone marrow cumulative exposure dose.

  • PDF

Class duplication prescriptions in patients taking fixed-dose combination antihypertensives (고혈압 복합제 복용환자에서 동일계열약물 중복 현황)

  • Koo, Hyunji;Lee, Ji Won;Choi, Ha Eun;Je, Nam Kyung;Jeong, Kyeong Hye
    • Korean Journal of Clinical Pharmacy
    • /
    • v.32 no.2
    • /
    • pp.125-132
    • /
    • 2022
  • Background: Fixed-dose combinations have the advantage of improving patient compliance, but may increase the risk of duplicate prescriptions. As the use of fixed-dose combination antihypertensives increases, it is necessary to investigate the current status of class duplication prescriptions (CDP) in patients taking fixed-dose combination antihypertensives in Korea and to identify factors associated with CDP. Methods: We conducted a retrospective observational study using nationally representative claim data. Hypertensive patients aged 20 years or older taking fixed-dose combination antihypertensives were extracted. Among these patients, patients with CDP were identified. A chi-square test was applied to determine the differences between patients with CDP and non-CDP. The associated factors of CDP were identified through multiple logistic regression. Results: Of the 74,165 patients who were prescribed fixed-dose combination antihypertensives, 426 patients (0.6%) with CDP were identified. The most common antihypertensive class associated with CDP was calcium channel blockers (194 patients, 45.5%), followed by angiotensin II receptor blockers (136 patients, 31.9%). Patients aged 75 years or older (odds ratio [OR] 1.83, 95% confidence interval [CI] 1.02-3.52), chronic kidney disease (OR 4.45, 95% CI 2.15-8.25), chronic heart failure (OR 2.71, 95% CI 1.93-3.72), coronary artery disease (OR 2.22, 95% CI 1.60-3.03) and Medical Aid/Patriots and Veterans Insurance (OR 1.49, 95% CI 1.04-2.07) were significantly associated with increased CDP. Conclusions: The factors associated with CDP were the elderly, comorbidities, and low socioeconomic status. Since CDP can result in negative clinical outcomes, active intervention by the pharmacist is warranted.